ADJUVANT CHEMOTHERAPY OF OSTEOGENIC-SARCOMA - PROGRESS AND PERSPECTIVES

被引：27

作者：

FREI, E

JAFFE, N

GERO, M

SKIPPER, H

WATTS, H

机构：

[1] SO RES INST, BIRMINGHAM, AL 35205 USA

[2] CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1978年 / 60卷 / 01期

关键词：

D O I：

10.1093/jnci/60.1.3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / 10

页数：8

共 30 条

[1]

BAND PR, 1975, CANCER, V36, P471, DOI 10.1002/1097-0142(197508)36:2<471::AID-CNCR2820360225>3.0.CO

[2]

2-4

[3]

BROCKMAN RW, 1974, ANTINEOPLASTIC IMMUN, P352

[4] DOXORUBICIN IN DISSEMINATED OSTEOSARCOMA [J].

CORTES, EP ;

HOLLAND, JF ;

SINKS, LF ;

WANG, JJ .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1972, 221 (10) :1132-&

[5] AMPUTATION AND ADRIAMYCIN IN PRIMARY OSTEOSARCOMA [J].

CORTES, EP ;

HOLLAND, JF ;

WANG, JJ ;

SINKS, LF ;

BLOM, J ;

SENN, H ;

BANK, A ;

GLIDEWELL, O .

NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (19) :998-1000

[6]

DJERASSI I, 1975, CANCER CHEMOTH REP 3, V6, P3

[7]

FREI E, 1975, NEW ENGL J MED, V292, P846

[8]

FREI E, 1972, CANCER RES, V32, P2593

[9]

FREI EMIL, 1965, ADVANCE CHEMOTHERAP, V2, P269

[10]

GOLDMAN ID, 1974, MOL PHARMACOL, V10, P275

← 1 2 3 →